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ABSTRACT
In 1992 nitric oxide (NO) was declared molecule of the year by Science magazine, and ever since
research on this molecule continues to increase. Following this award, NO was shown to be a
mediator/protector of ischemia and reperfusion injury in many organs, such as the heart, liver,
lungs, andkidneys.Controversyhas existed concerning the actual protective effects ofNO.However,
literature from the past 15 years seems to reinforce the consensus that NO is indeed protective. Some
of the protective actions of NO in ischemia and reperfusion are due to its potential as an antioxidant
and anti-inflammatory agent, along with its beneficial effects on cell signaling and inhibition of
nuclear proteins, such as NF-κ B and AP-1. New therapeutic potentials for this drug are also
continuously emerging. Exogenous NO and endogenous NOmay both play protective roles during
ischemia and reperfusion injury. Sodium nitroprusside and nitroglycerin have been used clinically
with much success; though only recently have they been tested and proven effective in attenuating
some of the injuries associatedwith ischemia and reperfusion. NO inhalation has, in the past, mostly
been used for its pulmonary effects, but has also recently been shown to be protective in other organs.
The potential of NO in the treatment of ischemic disease is only just being realized. Elucidation of
the mechanism by which NO exerts its protective effects needs further investigation. Therefore, this
paper will focus on the mechanistic actions of NO in ischemia and reperfusion injury, along with
the compound’s potential therapeutic benefits.
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INTRODUCTION
It has been over 200 years since the discovery of ni-
tric oxide (NO.) by John Priestly [1], and yet research
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on this small molecule is still increasing. In 1988 Bob
Furchgott proposed that endothelium-derived relax-
ing factor might be NO [2], and in 1992 NO was
named molecule of the year [3]. Since then many ar-
ticles have been published regarding its mechanism
of action and therapeutic potential, although without
complete consensus. NO has been shown to be re-
leased by the conversion of L-arginine to L-citrulline,
a reaction catalyzed by one of three NO syntheses
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Table 1. Brief review of the chemical and molecular protec-
tive effects of nitric oxide.
Effects as Description Sources
1. Antioxidant Free radical scavenger 14, 16
Inhibits cell respiration 17, 18
Restores antioxidant
enzyme levels
15
2. Anticytokines Suppresses TNF-α 22, 28, 29
Suppresses IL-1 31
3. Antiadhesion
molecules
Inhibits selectins 24, 34
Inhibits VCAM-1 and
ICAM-1
24, 36
4. Antiapoptotic Downregulataies gene
p53
44
Inhibits human
caspases
45, 47
Induces expression of
HSP70
48
5. Antichemokines Downregulates MIP-1
and MIP-2
51, 54
6. Antidetrimental
signaling
Regulates MAPKs 56, 58
Promotes
preconditioning
59
Produces elevated
levels of cGMP
60
7. Antinuclear proteins Inhibits NF-κB 63–66
Inhibits AP-1 68
(NOS): neuronal NOS, endothelial NOS, and inducible
NOS [4, 5]. Furthermore, NO has been shown to be a
mediator/protector of ischemia and reperfusion (I/R)
tissue-mediated injury [6]. NO has been shown to be
tissue-protective through its physiologic regulation of
vascular tone, inhibitionofplatelet aggregation, attenu-
ation of leukocyte adherence to the endothelium, scav-
enging of oxygen-derived free radicals, maintenance
of normal vascular permeability, inhibition of smooth
muscle proliferation, immune defenses, and stimula-
tion of endothelial cell regeneration [7]. Delivery of NO
during an ischemic insult has been shown to limit the
extent of reperfusion damage to the heart [8], liver [9],
lungs [10], and kidneys [11]. In the past there has been
debate concerningwhetherNO is protective. However,
themajority of literature from the past 15 years demon-
strates that NO is indeed protective, and that the dose
and timing of administration may have caused contro-
versy [8, 12, 13] (Tables 1 and 2). This paper focuses
on the mechanistic actions of NO in I/R injury and the
compound’s potential therapeutic benefits.
CHEMICAL ANDMOLECULAR EFFECTS
OF NITRIC OXIDE
Nitric Oxide as an Antioxidant
NO has been shown to have antioxidant properties not
related to alterations in neutrophil migration or ad-
hesion, which may account for much of the protective
effect ofNOduring I/R injury. The antioxidant proper-
ties of NO in tissues may be related to the reduction by
NO of superoxide anion-mediated tissue toxicity [13].
NO reacts with the superoxide anion to form peroxyni-
trite, which may act as a superoxide radical scavenger
[14] This action doesn’t allow peroxynitrite to perpetu-
ate the lipid peroxidation chain reactions, whichwould
result in the generation of other free radicals, such as
hydrogen peroxide (H2O2) and hydroxide [15]. Fur-
thermore, NO acts as an oxygen radical scavenger [16].
NO has also been shown to inhibit mitochondrial res-
piration [17, 18], and thereby reduces the generation
of reactive oxygen species after I/R injury, which can
contribute to cellular injury, necrosis, and apoptosis.
NO appears to modulate cell respiration by inhibiting
cytochrome-c oxidase before ischemia, which can cre-
ate an adaptive preconditioning environment [19]. NO
competes with oxygen for binding to cytochrome-c ox-
idase, so the interaction of NO with the electron trans-
port chain is more pronounced when there is less oxy-
gen, as in ischemia.When reperfusion occurs, ischemia
will slowly be relieved, preventing abrupt resump-
tion of the electron transport chain, and generation
of less reactive oxygen species [12]. The conversion of
H2O2 andmyoglobin to ferryl myoglobin has also been
shown to be prevented byNO, and this actionmay pre-
vent the initiation of lipid peroxidation [20]. Kawachi
and associates observed eNOS-deficientmice subjected
to a period of ischemia. They found that eNOS-derived
NO modulates I/R-induced injury to the liver. Their
model, however, did not involve the infiltration of
polymorphonuclear neutrophils, so it may have in-
volved enhanced reactive oxygen species-dependent
injury [21]. Rodriguez-Pen˜a and associates also demon-
strated that molsidomine, an NO donor, administered
15 min before reperfusion, prevented an increase in
superoxide anion due to I/R [22]. Additionally, it has
been shown thatpretreatment of ratswithmolsidomine
restores the depleted renal antioxidant enzymes, such
as glutathione, catalase, and superoxide dismutase
[15].
Anti-Inflammatory Effect of Nitric Oxide
Nitric Oxide has been found to be a mediator of many
inflammatory processes, including the prevention of
neutrophil infiltration [23] and the reduction of pro-
inflammatory cytokines [24]. These anti-inflammatory
responses are essential for the protection against
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Table 2. Selective review of the literature pertaining to the anti-ischemic and anti-inflammatory actions of NO·
Type of Animal
anti-inflammatory type and
Authors action ischemia time Treatment Results
Lo´pez-Neblina et al., 1995 [91] Less lipid peroxidation Rat, 75 min SNP, 60 min prior to
ischemia
Kidney injury
protective effect
Lo´pez-Neblina et al., 1996 [11] Prevention of
neutrophil infiltration
Rat, 75 min SNP at 75, 30, 15, and 5
min prior to reperfuion
Kidney injury
protective effect
Murakami et al., 1997 [10] Reduced PMN
sequestration
Rat, 60 min Inhaled NO, during
ischemia, at reperfusion
15 min after reperfusion
Lung injury protective
effect
Massoudy et al., 2000 [78] Less activated
leukocytes and
platelets
Human SNP, 60 min of reperfusion Heart injury protective
effect
Martinez-Mier et al., 2000 [44] Diminished apoptosis Rat, 75 min SNP, 15 min before
reperfusion
Kidney injury
protective effect
Aiba et al., 2001 [92] Improved hepatic
mircocirculation
Dog, 60 min FK409, intravenously for
30 min
Liver injury protective
effect
Martinez-Mier et al., 2002 [51] Downregulated MIP-1
and MIP-2
Rat, 75 min SNP, 15 min prior to
reperfusion
Kidney injury
protective effect
Cakir et al., 2003 [93] Reduced neutrophil
infiltration
Dog, 120 min SNP, after release of aortic
cross-clamp
Lung injury protective
effect
Anaya-Prado et al., 2003 [94] Reduced cytokine
expression
Rat, 90 min SNP, at 30 min after
bleeding began
Hemorrhagic shock
protection
Rodriguez-Pen˜a et al., 2004
[22]
Reduced
pro-inflammatory
cytokines
Rat, 60 min Molsidomine, 15 min
before reperfusion
Kidney injury
protective effect
Kuroki et al., 2004 [77] Increased hepatic
microcirculation
Rat, 60 min SNP, continuously during
reperfusion
Kidney injury
protective effect
Chander et al., 2005 [15] Restored antioxidant
enzymes
Rat, 45 min L-arginine, 30 min before
reperfusion and
molsidomine, 30 min
before ischemia, 12 h
after reperfusion
Kidney injury
protective effect
Garreffa et al., 2006 [95] Coronary vasodilation Rat, 1.5 h SNP, 30 min before and
throughout metabolic
inhibition
Heart injury protective
effect
Liu et al., 2007 [87] Reduced leukocyte
infiltration
Pig, 50 min Inhaled NO, 10 min before
balloon deflation and
through reperfusion
Heart injury protective
effect
Chattopadhyay et al., 2008
[89]
Reduced neutrophil
infiltration
Rat, 60 min L-arginine, 6 days prior to
ischemia/reperfusion
Liver injury protective
effect
tissue I/R injury (Table 2). Next, we will introduce the
molecular inflammatory protection given by NO.
Nitric Oxide as an Anti-TNF and Anti-IL-1
Agent
Nitric Oxide has been shown to mediate the expres-
sion of tumor necrosis factor (TNF), a well-known
cytokine, which seems to induce the accumulation
of neutrophils by indirect mechanisms involving the
macrophage, and induces the production of other cy-
tokines [22, 25] (Figure 1). Upon reperfusion, TNF-α
has been shown to act as a continuous stimulant for
polymorphonuclear neutrophil infiltration in the liver,
a critical event in I/R injury [26]. TNF-α has also been
suggested to stimulate chemokine synthesis in ischemic
tissues, and to activate NF-κB, a transcription factor
involved in the regulation of genes related to the in-
flammatory response [27]. NO donors administered
48
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Figure 1. Possible mechanistic effects on the role of ischemic
injury and exogenous NO in organ protection. During
ischemic injury there is a downregulation of NO in the cell.
However, if an exogenous NO donor is administered during
the ischemic insult, NO concentrations can be elevated. This
elevated level of NO may be able to inhibit gene p53
activity, decrease levels of pro-inflammatory cytokines and
chemokines, as well as decrease levels of cell adhesion
molecules. Specifically, TNF-α, IL-1, MIP-1, and MIP-2 are
the cytokines and chemokines which are reduced by NO.
Through the suppression of gene p53 and lowered levels of
TNF-α and IL-1 in the cell, the amount of apoptosis can be
reduced. And through the suppression of cell adhesion
molecules and lowered levels of MIP-1 and MIP-2
α-chemokines, less neutrophil infiltration can occur.
Decreased apoptosis and neutrophil infiltration help to
protect the cell during ischemia and reperfusion and lead to
a decrease in organ injury.
during the ischemic event appear to suppress TNF-α
[28]. The effect of direct intrarenal administration of
molsidomine, a known NO donor, on renal dysfunc-
tion and inflammatory reaction after I/R was inves-
tigated by Rodriguez- Pen˜a et al. They measured the
levels of pro-inflammatory cytokines 48 h after blood
flow re-establishment and found that treatment with
molsidomine significantly lowered the levels of TNF-
α. They determined that molsidomine exerted protec-
tive effects on renal function when administered dur-
ing the ischemic period. This protective action seemed
to be mediated, in part, by the reduction of pro-
inflammatory cytokines, such as TNF-α [22]. Anaya-
Prado and associates investigated the effects of another
NO donor, nitroprusside, on the lung after I/R injury.
The effect of this NO donor on pro-inflammatory cy-
tokines was measured by ribonuclease-protection as-
say, and they found that the expression of all cytokines,
including TNF-α, was reduced by sodium nitroprus-
side [29]. Hatano et al. have investigated the effect of
a NO donor, S-nitroso-N-acetylpenicillamine (SNAP),
on TNF-α-mediated apoptosis. TNF-α moderated cell
death in iNOS (-/-) mice demonstrated the protective
actions of NO against TNF-α-mediated apoptosis [30].
The expression of another cytokine, interleukin-1 (IL-
1), also appears to be mediated by NO. IL-1 is a pro-
inflammatory cytokine, which can contribute to the
deleterious effects of I/R injury [26]. Franco-Gou and
associates demonstrated that preconditioning through
NO inhibits IL-1 release, and this is the method by
which NO exerts its protective effects against hepatic
I/R [31].
Nitric Oxide as an Anti-Adhesion Molecule
The expression of cell adhesion molecules (CAMs),
such as the selectins, is also influenced by NO. Af-
ter I/R injury, CAMs are upregulated in the cell due
to activation induced by a variety of inflammatory
molecules, including cytokines and chemokines [32].
Selectins have been shown to mediate the initial at-
tachment between polymophonuclear neutrophils and
activated endothelium, a requisite step in the I/R in-
jury model [33]. P-selectin plays a role in the early
phase of rolling and adherence of leukocytes in the
microvasculature after ischemia reperfusion. Our lab
has shown that P-selectin (-/-) animals were more
protected than controls at 3 h after ischemia, con-
firming the key role of P-selectin in liver I/R injury.
Furthermore, I/R has been shown to produce a de-
crease in NO levels and an increase in P-selectin lev-
els in the cell [34]. This increase in P-selectin levels
may be due to superoxide and H2O2 levels in the
cell. It has also been demonstrated that infusion of
a NO donor decreased leukocyte rolling and adher-
ence, and prevented P-selectin expression on the sur-
face on the venular endothelium [35]. De Caterina
and associates have demonstrated the effects of NO
on cytokine-induced expression of effector molecules
characteristic of endothelial activation. Using three
different NO donors they showed that NO inhibits
other cell adhesion molecules, such as vascular cell
adhesion molecule-1 (VCAM-1), intercellular adhesion
molecule-1 (ICAM-1), and endothelial-leukocyte adhe-
sionmolecule-1 (E-selectin) [24]. The long-termeffect of
NO on cell adhesion molecules has also, more recently,
been demonstrated by Waldow et al. They demon-
strated that SNAP administration reduced the induc-
tionofVCAM, ICAM, andE-selectin by the chemokines
TNF-α and IL-1β [36]. Jiang et al. also investigated
the cell surface and mRNA expression of adhesion
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Figure 2. NO and its effects on cell-signaling pathways. A clamp can be applied to the blood vessels to experimentally induced
ischemia in cells. During this induced ischemia an exogenous NO donor can be administered into the blood. This NO then
migrates into the cell where it can afford protection during ischemia. NO can also be endogenously released in the cell by the
conversion of L-arginine to L-citrulline. Once in the cell NO gives protection through many pathways. NO can inhibit
cytochrome oxidase in the mitochondria to reduce the amount of free radicals produced. NO can also inhibit TNF-α, which goes
on to inhibit NF-κB. NF-κB can then inhibit MAPKs, which include p38, ERK, and JNK. The downregulation of p38 can then
lead to the inhibition of caspase-3 and gene p53. Overall, the downregulation of p53, ERK, and JNK can lead to a decrease in cell
inflammation. NO is also protective through its stimulation of sGC, which goes on to increase cGMP levels in the cell. cGMP has
the potential to inhibit caspase-3 activity, which would otherwise be necessary for apoptosis. The decrease in cell inflammation
and apoptosis due to elevated levels in the cell can lead to an increase in organ protection during ischemia and reperfusion.
molecules, E-selectin, ICAM-1, and VCAM-1, in hu-
man dermal microvascular endothelial cells exposed
to the NO donor, spermine NONOate. They found
that these CAMs, which are induced by TNF-α, are re-
duced upon treatment with spermine NONOate, pos-
sibly by blocking redox-regulated NF-κB activation
[37].
The Anti-Apoptotic Effect of Nitric Oxide
Different mechanisms cause NO to exhibit a proapop-
totic or antiapoptotic effect [38, 39] (Figure 2). How-
ever, the amount of apoptosis induced by TNF-α, ox-
idative stress, and serum or glucose deprivation has
been shown to be decreased by NO. When there are
high NO concentrations in the cell, necrosis and apop-
tosis occur, such as when cells are exposed to high
levels of exogenous NO donors [40, 41]. Nonetheless,
application of aNOdonor in some cells, such as hepato-
cytes, human B-lymphocytes, endothelial cells, spleno-
cytes, eosinophils, and PC12 cells, inhibits apoptosis
[42]. This may be due to a diminished response of
guanylyl cyclase to NO, although the mechanism by
which NO inhibits apoptosis may vary between cell
types [42, 43]. NO in our lab has also been shown to
inhibit apoptosis by downregulating the expression of
gene p53, which normally promotes apoptosis in the
kidneys. Animals with worse histopathological fea-
tures, after I/R injury, were found to have elevated
levels of p53 gene expression. From this study we
confirmed the beneficial effects of an exogenous NO
donor during an ischemic insult and demonstrated
that the downregulation of gene p53 correlated with
a decrease in apoptosis [44]. Furthermore, NO has
been demonstrated to dose-dependently inhibit re-
combinant human caspases, a family of cysteine pro-
teases that play a critical role in the initiation and
execution of apoptosis [45]. The caspase cascade ac-
tivation is required for p53-dependent apoptosis [46].
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The ability of NO to inhibit caspases [47] is due to S-
nitrosylation of the cysteine thiol in the presence NO.
In addition, NO has been shown to induce the ex-
pression of heat shock proteins, such as HSP70, which
have been depicted to protect hepatocytes from apop-
tosis [41]. Kim and associates demonstrated the ef-
fect of NO on HSP70. They found that NO is able
to induce HSP70, and that this induction protected
rat liver cells from TNF-α apoptosis [48]. The influ-
ence of inhaled NO on apoptosis induced after I/R
has been investigated by Yamashita et al. Inhaled NO
during reperfusion greatly attenuated the increase of
TUNEL-positive cells in ischemia-reperfusion. They
demonstrated that inhaled NO attenuated apopto-
sis after pulmonary I/R injury [49]. Appropriate
amount of NO seem to suppress unwanted apoptosis
[50].
Nitric Oxide as an Anti-Chemokine: MIP-1
and MIP-2
NO has been shown to regulate the chemokine re-
sponse,which includesmacrophage inflammatorypro-
teins MIP-1 and MIP-2. These chemokines have been
shown to act as neutrophil chemoattractants [25]. Is-
chemia and reperfusion injury is dependent on neu-
trophil infiltration, so MIP-1 and MIP-2 contribute to
the detrimental effects of reperfusion. Moreover, NO
can regulate the chemokine response througha series of
signaling pathways, potentially those associated with
MAPK, SAPK/JNK, and JAK/STAT [51]. Candrasekar
and associates demonstrated that I/R induces the ex-
pression of MIP-2, and that MIP-2 was present in in-
filtrating cells [52]. Our lab investigated the role that
exogenous NO, from the NO donor sodium nitroprus-
side, plays on the regulation of MIP-2 and MIP-1 α-
chemokines. The relationship between NO and MIP-2
and MIP-1 α-chemokines was confirmed, and we no-
ticed that NO downregulated the production of these
chemokines after I/R injury [51]. Recently the role
of NO in MIP-2 production has been investigated by
Shibata and associates. They first demonstrated that
ERK1/2 is involved in MIP-2 production [53]. Then
they showed that NO suppressed activation of ERK1/2
and NF-κB [54]. Walpen and associates also investi-
gated the relationship between NO and MIP-2. They
exogenously administered DETA-NO, an NO donor,
to rat mesangial cells, and contradictory to what we
saw, observed an increase in MIP-2 expression. They
then determined that NOproduced by neutrophils and
mesangial cells has the potential to amplify leukocyte
recruitment [55]. This may have been due to the dose
given, timing, or the cell environment in which the NO
donor was administered.
Anti-Detrimental Signaling of Nitric Oxide
Nitric Oxide appears to be an important modula-
tor of mitogen-activated protein kinases (MAPKs).
MAPKs can transduce signals into cellular responses
by modulating gene and protein expression involved
in cell differentiation, proliferation, survival, and death
[38]. Some of the MAPKs include extracellular signal-
regulated kinases (ERK), c-Jun N-terminal kinases
(JNK), and p38 kinases [45, 56]. These MAPKs are ac-
tivated due to early events of I/R, including the ac-
tivation of TNF-α and other proteins [57]. ERK, p38
MAPK, and JNK have been shown to be activated by
NO-related species and to participate in NO signal
transduction [56]. Nitric Oxide influences downstream
MAPK activation through the nitrosylation of critical
thiol residues, which possibly activates specific protein
kinase C (PKC) isoforms. The post-translation modifi-
cation of lowmolecular weight G proteins is the mech-
anism by which NO may signal independent of PKC
[58]. NO has been shown to promote beneficial signal-
ing during preconditioning, a process which can pro-
tect organs from I/R injury.Carini andassociates inves-
tigated the mechanism by which NO exerts beneficial
effects. They concluded that NO can induce precon-
ditioning of hepatocytes by promoting the sequential
activation of guanylate cyclase, cGK, and p38 MAPK
[59]. A recent study by Wang et al. sought to investi-
gate the role of p38MAPKsignal transduction pathway
on apoptosis induced by NO. They demonstrated the
p38 signal transduction pathway of NO-induced artic-
ular chondrocyte apoptosis in a rabbit model. Further-
more, they showed that p38 is able to stimulate NF-κB,
p53, and caspase-3 activation, which can lead to chon-
drocyte apoptosis [40]. It has also been suggested that
MAPKs can intensify inflammatory signaling, and that
the appropriate inhibition of MAPKs could potentially
help ameliorate the ischemic response [57]. NOhas also
been shown to activate sGC,which leads to an elevation
of cyclic GMP (cGMP). cGMP, through downstream ef-
fectors, has been shown to regulate neurotransmission,
cell migration, proliferation, differentiation, survival,
axon outgrowth and guidance, and visual signal trans-
duction [60]. One of these mechanisms regulated by
cGMP may be the process by which NO exerts benefi-
cial signaling during I/R injury.
Anti-Nuclear Protein Effect of Nitric Oxide
Nitric Oxide has been shown to inhibit bothNF-κB and
AP-1 transcription factors, which have been shown to
play important roles in I/R injury. NF-κB has been
shown to be activated by cytokines, such as TNF-α
[57], and by free radicals. Furthermore, the genes regu-
lated by this transcription factor include those involved
in the inflammatory response, cell adhesion, and
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apoptosis [27, 61]. The genes regulated by NF-κB in-
clude iNOS, TNF-α, IL-1, and IL-6 [62]. NO has been
shown to inhibit NF-κB activation, possibly through
the induction of IkB-α [63] or by nitrosylating a redox-
active cysteine residue in NF-κB that would attenuate
binding to DNA. It is also possible that the inhibition
of NF-κB by NO occurs because of its scavenging of
the superoxide radical, which could otherwise activate
NF-κB [64, 65]. Matthews and associates investigated
the ability of an NO donor to influence DNA bind-
ing activity of NF-κB. They used sodium nitroprus-
side and S-nitroso-N-acetylpenicillamine and found
that NO donors could inhibit the DNA binding of NF-
κB. They proposed that NO donors inhibited NF-κB
by stabilizing IkBα and increasing the transcription of
IkBα genes [66].
Nitric Oxide has also been demonstrated to inhibit AP-
1 activity. AP-1 contributes to post-I/R injury, due to
its possible involvement in intracellular signaling path-
ways leading to apoptosis, or via its involvement in
signaling events triggered by cytokines, such as TNF-
α [67]. Tabuchi and associates investigated the effects
of an NO donor, sodium nitroprusside, on the tran-
scription factor AP-1. They concluded that cells admin-
istered SNP-experienced attenuation of AP-1. Potas-
sium ferrocyanide, an analogue of SNP devoid of NO,
was unable to inhibit the increase in tissue plasmino-
gen activator (TPA)-responsive element-binding activ-
ity induced by kainite. This failure of potassium fer-
rocyanide supports the involvement of NO in AP-1
attenuation [68].
Therapeutic Potential of Nitric Oxide
The literature amply demonstrates that following I/R
there is a deficit of NO in the cell. Thus, it seems plau-
sible, and has been shown in the heart [8], liver [69],
lungs [70], and kidneys [71] that administration of NO
during I/R may help to attenuate subsequent injury.
Exogenous Nitric Oxide Donors
Nitric Oxide donors, such as nitroprusside and the or-
ganic nitrate nitroglycerin, have been used clinically
with success. Sodium nitroprusside is mainly used to
treat hypertensive emergencies; however, it can also
be used when short-term reduction of cardiac preload
and/or afterload is desired [72]. Cyanide toxicity is
a concern in the administration of sodium nitroprus-
side, although it is relatively uncommon in the surgical
intensive care unit [73], and may be avoided by com-
bination with another drug, such as trimetaphan or a
β-adrenergic receptor blocker [74]. On the other hand,
nitroglycerin has many more therapeutic options, as in
the treatment of angina, congestive heart failure, unsta-
ble anginapectoris, non-ST-segment-elevationmyocar-
dial infarction, acute myocardial infarction, and vari-
ant angina [72]. Tolerance to nitroglycerin can occur
with long-term usage, but the vitamins C or E, which
are antioxidants, alongwith the organic nitrate therapy
have been shown to prevent tolerance to the drug [75].
Our lab, in 1995, demonstrated the beneficial effects
of nitroprusside on the ischemically damaged rat kid-
ney, concluding that exogenous NO is beneficial and
protective to the kidney during I/R [76]. These ben-
eficial effects have more recently been demonstrated
again by Kuroki and associates, who administered ni-
troprusside to the rat kidney during reperfusion and
found increased hepatic microcirculation and reduced
hepatocyte damage [77]. We also investigated the time
dependence of sodium nitroprusside administration in
the rat ischemic kidney. Administration of sodium ni-
troprusside occurred at 75, 30, 15, and 5 min before
reperfusion. We concluded that sodium nitroprusside
could be administered as late as 15 min before reper-
fusion and still be effective in the rat ischemic kidney
[11]. NO donors have also been used experimentally
with success to improve cardiac [8, 78], pulmonary [70,
79], and liver [22, 80] I/R injuries. Many NO donors,
other than nitroprusside and nitroglycerin, exist and
each demonstrates different modes and rates of NO
release. These include spontaneously releasing NO in
solution, releasing NO over a prolonged period of time
at steady rates, or releasing NO in specific tissues [81,
82]. Therefore, anNOdonormay be specifically chosen
for the disease it will treat [3].
Direct Nitric Oxide Donor: NO Inhalation
Inhaled NO has been used in the past because of its
pulmonary effects, but its possible therapeutic use as
a mediator of I/R injury is being investigated [75].
The clinical applications of inhaled NO include per-
sistent pulmonary hypertension of the newborn [83],
bronchopulmonary dysplasia, and pulmonary hyper-
tension in adults [84]. Barbotin-Larrieu and associates
showed that, in a neonatal piglet model of lung I/R,
inhaled NO could prevent microvascular injury, en-
dothelial dysfunction, and pulmonary neutrophil ac-
cumulation. Thus, inhaled NO prevented some of the
reperfusion-induced injury [85]. The timing and con-
centration of inhaled NO are vital to its protective ef-
fects, and Murakami et al. have investigated these fac-
tors. They found that I/R injury is best attenuated by
NO at 30 ppm given immediately at reperfusion or 15
min after the beginning of reperfusion [10]. Schutte and
associates have also shown that inhaled NO induces a
state of preconditioning and maintains endothelial in-
tegrity in subsequent I/R [86]. Inhaled NO has mostly
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been studied in the ischemic lung; however, it has been
shown to be effective in other organs as well. The effect
of NO after myocardial I/R was investigated by Liu et
al. They showed improvement in microvascular per-
fusion and reduction of infarct size after inhalation of
NO just before and during coronary reperfusion [87].
Inhaled NO following orthotopic liver transplantation
has, very recently, been investigated byLang et al. They
demonstrated that inhaled NO at 80 ppm, given to
patients undergoing orthotopic liver transplantation,
significantly lowered hepatocyte apoptosis, thereby re-
ducing the injury related to I/R [88]. Inhaled NO has
been shown numerous times to be effective in models
of I/R and even in human clinical trials, again demon-
strating the effectiveness of exogenously administered
NO.
Endogenous NO: L-Arginine
L-arginine is an endogenous source of NO, which
is released during the conversion of L-arginine to
L-citrulline. Administration of L-arginine can be
protective to ischemic organs. Chander and associates
investigated the effects of L-arginine administration in
I/R-induced renal failure in rats. The L-arginine ad-
ministration occurred 30min before the renal ischemia,
and pretreatment with this drug attenuated renal dys-
functions andmorphological alterations, improved the
tissue as well as urine NO contents, reduced elevated
thiobarbituric acid reactant (TBAR) levels and restored
depleted renal antioxidant enzymes [15]. Chattopad-
hyay and associates have also presented results that
support the protective function of L-arginine in rat
liver I/R. They administered L-arginine, 100 mg/kg
body weight/daily for 7 days before induced I/R, and
found heightenedNOproduction in hepatocytes along
with diminished hepatocellular injury in rats that re-
ceived this treatment. They concluded that L-arginine
wasprotective in rat liver I/R, and that itwasprotective
due to increased production of NO [89]. Furthermore,
we investigated the effects of L-arginine in the lung af-
ter hemorrhagic shock and resuscitation. Our findings
showed that L-arginine was protective to the injured
lung due to reduction in acute lung injury observed
in the histological studies [29]. However, a more re-
cent study by Rusai et al. in the ischemic rat kidney,
observed that L-arginine (2 g/kg body weight daily)
didn’t affect the injury sustained from I/R, but did in-
crease the mRNA expression of NOS isoforms. This
may be explained by time and dose administration dif-
ferences between studies, alongwith the severity of the
ischemic injury [90]. Again, more studies examining
the ideal dose and time of administration of L-arginine
will be helpful in determining its possible therapeutic
value.
CONCLUSION
Themechanisms by which NO exerts protective effects
in I/R injury have eluded discovery for many years.
We are only just beginning to understand the com-
plex mechanism of action of NO. It protects against
I/R injury due to its potential as an antioxidant and
anti-inflammatory agent, as well as its beneficial effects
on cell signaling and its inhibition of nuclear proteins.
Consensus is being reached in the debate regarding
an NO protective effect, with most studies reporting
its protective effects. The mechanism of this protection
requires further investigation. More therapeutic possi-
bilities for NO continue to be suggested, including the
potential of NO as an agent to attenuate I/R injury.
The ideal time and dose of NO administration need to
be clearly delineated so that clinical trials of this drug
can be performed, and its potential in preventing I/R
injury can be reached.
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